<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57193">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113033</url>
  </required_header>
  <id_info>
    <org_study_id>NVNS01</org_study_id>
    <nct_id>NCT02113033</nct_id>
  </id_info>
  <brief_title>VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients</brief_title>
  <acronym>VANGUARD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Sorin Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorin Group</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation
      for the treatment of congestive heart failure with reduced ejection fraction, and to report
      secondary measures of efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome measure is the freedom from Serious Adverse Device Effects, defined as the number of patients without SADEs.</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse device effects will be sub-classified into device-related or procedure-related, when the adverse event has a generic cause independent from the device itself and occurs within 30 days of the implant procedure.</description>
  </primary_outcome>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Equilia®  Vagal Nerve Stimulation</intervention_name>
    <description>Vagal Nerve Stimulation synchronized with cardiac activity</description>
    <other_name>Device used: Equilia®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Left ventricular dysfunction of ischemic or idiopathic dilated cardiomyopathy
             etiology, characterized by LVEF &lt; 40%

          2. Chronic heart failure with symptoms characterized by NYHA functional class II or III
             at the time of enrollment despite optimal drug regimen

          3. Optimal drug regimen as defined in the current European guidelines

          4. Sinus rhythm, with spontaneous heart rate ≥ 60bpm at the time of enrollment

          5. Signed and dated informed consent

        Main Exclusion Criteria:

          -  Patient implanted with or eligible to cardiac pacing as per current guideline

          -  Risk for neck surgery in the electrode zone within a year after enrollment

          -  Patient with right carotid artery stenosis

          -  Symptomatic hypotension

          -  History of peptic ulcer disease or upper gastrointestinal bleeding

          -  Asthma, severe COPD, or severe restrictive lung disease

          -  Advanced Diabetes Mellitus

          -  Recent acute myocardial infarction, coronary artery surgery or revascularization (or
             already planned)

          -  Recent cerebro-vascular event

          -  Significant valvulopathy

          -  Advanced Renal failure

          -  Previous heart transplant or current LVAD device therapy

          -  Life expectancy &lt; 1 year for non-cardiac cause

          -  Patient included in another clinical study that could confound the results of this
             study

          -  Inability to understand the purpose of the study or to perform the procedures of the
             study

          -  Unavailability for scheduled follow-up

          -  Age of less than 18 years or under guardianship

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
